Us Bancorp \De\ Karuna Therapeutics, Inc. Transaction History

Us Bancorp \De\

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$161.01 - $317.85 $27,210 - $53,716	169 Added 25.57%	830 $262,000
Q3 2023 Nov 03, 2023	SELL	$164.66 - $218.08 $336,565 - $445,755	-2,044 Reduced 75.56%	661 $111,000
Q2 2023 Aug 09, 2023	SELL	$176.32 - $240.22 $34,206 - $46,602	-194 Reduced 6.69%	2,705 $586,000
Q1 2023 May 09, 2023	SELL	$161.33 - $204.36 $113,737 - $144,073	-705 Reduced 19.56%	2,899 $526,000
Q4 2022 Feb 13, 2023	BUY	$191.53 - $236.82 $3,639 - $4,499	19 Added 0.53%	3,604 $708,000
Q3 2022 Oct 27, 2022	SELL	$123.79 - $277.42 $98,660 - $221,103	-797 Reduced 18.19%	3,585 $807,000
Q2 2022 Aug 01, 2022	BUY	$93.97 - $143.33 $353,515 - $539,207	3,762 Added 606.77%	4,382 $554,000
Q1 2022 May 11, 2022	BUY	$98.9 - $132.37 $3,956 - $5,294	40 Added 6.9%	620 $79,000
Q3 2021 Nov 10, 2021	SELL	$101.2 - $125.87 $20,746 - $25,803	-205 Reduced 26.11%	580 $71,000
Q2 2021 Aug 05, 2021	SELL	$107.45 - $135.95 $169,771 - $214,800	-1,580 Reduced 66.81%	785 $90,000
Q1 2021 Apr 28, 2021	SELL	$95.46 - $133.08 $167,627 - $233,688	-1,756 Reduced 42.61%	2,365 $284,000
Q4 2020 Feb 04, 2021	SELL	$75.23 - $109.23 $103,441 - $150,191	-1,375 Reduced 25.02%	4,121 $419,000
Q3 2020 Nov 10, 2020	BUY	$71.31 - $109.74 $299,359 - $460,688	4,198 Added 323.42%	5,496 $425,000
Q2 2020 Aug 07, 2020	BUY	$62.14 - $117.21 $15,472 - $29,185	249 Added 23.74%	1,298 $145,000
Q1 2020 May 13, 2020	BUY	$60.41 - $115.92 $40,112 - $76,970	664 Added 172.47%	1,049 $76,000
Q4 2019 Feb 04, 2020	BUY	$11.44 - $123.99 $4,404 - $47,736	385 New	385 $29,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.